Ibrutinib, Obinutuzumab Are Early Tests Of How Fast Breakthrough Reviews Will Be
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ibrutinib application is among the first for a breakthrough therapy designee and should provide an early indicator of FDA review expectations for the newest expedited approval program.